Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Baltimore Marriott Waterfront

Feb 04, 2024 9:00 AM - Feb 04, 2024 4:00 PM

700 Aliceanna Street , Baltimore, MD 21202

Short Course: Aggregate Safety Assessment Planning (ASAP) Process

This is a In-Person Pre-Conference Short Course in conjunction with the Global Pharmacovigilance and Risk Management Strategies Conference


*Short Courses require an additional registration fee. You do not need to be registered for the forum to attend*


An Aggregate Safety Assessment Planning (ASAP) process is critical to ensure collection and assessment of product level data to answer key safety questions from various stakeholders. In addition, the ASAP process strengthens safety signal detection as well as risk identification and management. The Drug Information Association–American Statistical Association Interdisciplinary Safety Evaluation (DAISE) scientific working group has proposed an ASAP template to guide sponsor teams in clinical development. This session will describe how the ASAP supports multidisciplinary safety planning, ongoing aggregate safety evaluation, IND safety reporting decisions, and evaluation of product level safety data and the Safety Topics of Interest, which have the potential to influence a product’s benefit:risk assessment.


Plans are nothing; planning is everything.
–Dwight D Eisenhower


Registration for Live Short Course will be accepted onsite, or until capacity has been reached. Register prior to guarantee your seat.

Receive $150 off your forum registration by registering for any combination of at least two short courses and/or primers as well as the main forum. Purchases must be made at the same time to receive the discount. Discounts will be reflected on the last page of the cart.

Learning objectives

Upon completing this course, attendees will be able to:
  • Identify Safety Topics of Interest (STOI) for a product and plan for their evaluation during clinical development
  • Analyze the requirements for aggregate IND safety reporting
  • Evaluate accumulating program-level safety information to support ongoing characterization of the product safety profile and prepare for regulatory filing activities and responses to regulatory queries
  • Evaluate FDA Medical Queries (FMQs) and Standard Safety Tables and Figures

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.